The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.
Related stories
‘Superintelligence’ may never arrive, Deutsche Bank says. What that could mean for the U.S. economy.
NI company in talks to save Poundland from administration
How not to revive Europe’s auto industry
Who should pay for a birthday dinner? I always treat my guests.
White House asks US envoy to Greece Kimberly Guilfoyle to resign
Why one hedge-fund billionaire believes stocks are heading for a ‘really challenging’ 2027